Which statement about extended-release formulations with respect to exposure is commonly observed?

• A. They have less predictable exposure than immediate-release.
• B. They produce higher Cmax than immediate-release.
• C. They provide more predictable exposure and slower, more prolonged absorption.
• D. They reach steady state more slowly but with higher Cmax.

Answer: (C)

Extended-release formulations release the drug gradually over time, creating a slower, more sustained absorption. This smooths the plasma concentration–time profile, reducing peak levels and spreading exposure over a longer period. As a result, overall exposure becomes more predictable across dosing occasions, with smaller fluctuations between high and low concentrations. In contrast, choosing an immediate-release pattern tends to produce quicker and more variable absorption, leading to greater variability in exposure. The idea that these formulations would give higher peak concentrations or reach steady state more slowly with higher peaks doesn’t fit the pharmacokinetic goal of ER design, which is to smooth and prolong exposure rather than amplify peaks.